LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

Amgen posts Phase 3 trial win for Repatha (AMGN:NASDAQ)

Amgen (AMGN) stock is in focus as its cholesterol drug Repatha succeeds in a Phase 3 trial, reducing the risk of major adverse cardiovascular events. Read more here.

Amgen says its cholesterol shot prevented heart problems in a broad population

The results of the trial of Repatha in a 12,000-patient study could help the drug reach a large market, analysts say.

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha®...

Amgen claims ‘landmark’ study result that could widen heart drug’s use

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.

Evolocumab Reduces Risk of MACE for Patients Without Prior History of Heart Attack, Stroke

Amgen launches AmgenNow, which is a new direct-to-patient program that will start with evolucumab.

Amgen’s Phase III data supports FDA label expansion of Repatha

Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.